Since stepping down from his post at the Food and Drug Administration last year, Anand Shah has gone from toiling on the country’s Covid-19 response to updating his LinkedIn with a flurry of new advisory roles at promising startups.
On Wednesday, Shah, who was previously deputy commissioner for medical and scientific affairs, added another job to his profile. He will become the newest member of the board of mental health app developer Big Health, which last week announced it had raised $75 million in new funding led by Japanese mega-investor SoftBank. It’s the fourth board position Shah has taken on in recent months.
Big Health is a leading company in the field of digital therapeutics, or software used to help treat or manage medical conditions. The company has conducted extensive clinical testing of its products Daylight and Sleepio, which use cognitive behavioral therapy to treat anxiety and insomnia respectively. But unlike prescription digital therapeutics developers, Big Health has chosen not to pursue regulatory clearance for its products. Instead Big Health sells them to employers under less stringent FDA policies for certain types of products.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
